Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Number 5: Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to ...

USFDA, via email communication dated 11th April, 2025 (received by Medispray), has classified the inspection at the ...

Divi's Laboratories Limited has announced the signing of long-term manufacturing and supply agreement with a global pharma company for manufacturing and supply of advanced intermediates.